Roland E. Knoblauch

4.5k total citations · 1 hit paper
85 papers, 2.2k citations indexed

About

Roland E. Knoblauch is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Roland E. Knoblauch has authored 85 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Pulmonary and Respiratory Medicine, 44 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Roland E. Knoblauch's work include Lung Cancer Treatments and Mutations (47 papers), Sarcoma Diagnosis and Treatment (20 papers) and Colorectal Cancer Treatments and Studies (16 papers). Roland E. Knoblauch is often cited by papers focused on Lung Cancer Treatments and Mutations (47 papers), Sarcoma Diagnosis and Treatment (20 papers) and Colorectal Cancer Treatments and Studies (16 papers). Roland E. Knoblauch collaborates with scholars based in United States, South Korea and Spain. Roland E. Knoblauch's co-authors include Michael J. Garabedian, Michael I. Ebright, P Di Marzio, Trilok Parekh, Margaret von Mehren, George D. Demetri, Alexander I. Spira, Robert G. Maki, Shreyaskumar Patel and Robin L. Jones and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Roland E. Knoblauch

80 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

2015 576 citations George D. Demetri, Margaret von Mehren et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roland E. Knoblauch United States	22	1.3k	1.1k	738	247	225	85	2.2k
Collin M. Blakely United States	21	772 0.6×	808 0.7×	800 1.1×	74 0.3×	406 1.8×	75	2.1k
Tsung‐Teh Wu United States	30	1.2k 0.9×	685 0.6×	404 0.5×	52 0.2×	184 0.8×	88	3.3k
Tobias Heintges Germany	28	454 0.4×	980 0.9×	352 0.5×	39 0.2×	201 0.9×	93	4.5k
Joyce Steinberg United States	21	884 0.7×	980 0.9×	503 0.7×	18 0.1×	534 2.4×	58	2.6k
Dagmar Hess Switzerland	20	368 0.3×	897 0.8×	880 1.2×	39 0.2×	267 1.2×	61	1.7k
M. Naveed Shaik United States	19	523 0.4×	834 0.7×	1.1k 1.4×	20 0.1×	134 0.6×	42	2.1k
Javier Gómez‐Román Spain	27	1.1k 0.8×	937 0.8×	899 1.2×	306 1.2×	438 1.9×	140	2.9k
Robert Stagg United States	24	624 0.5×	1.4k 1.2×	824 1.1×	28 0.1×	210 0.9×	61	3.3k
Shannon R. Morris United States	23	354 0.3×	872 0.8×	980 1.3×	15 0.1×	179 0.8×	57	2.0k
Raymond Tubbs United States	28	375 0.3×	936 0.8×	815 1.1×	50 0.2×	364 1.6×	72	2.5k

Countries citing papers authored by Roland E. Knoblauch

Since Specialization

Citations

This map shows the geographic impact of Roland E. Knoblauch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roland E. Knoblauch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roland E. Knoblauch more than expected).

Fields of papers citing papers by Roland E. Knoblauch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roland E. Knoblauch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roland E. Knoblauch. The network helps show where Roland E. Knoblauch may publish in the future.

Co-authorship network of co-authors of Roland E. Knoblauch

This figure shows the co-authorship network connecting the top 25 collaborators of Roland E. Knoblauch. A scholar is included among the top collaborators of Roland E. Knoblauch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roland E. Knoblauch. Roland E. Knoblauch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Passaro, Antonio, Byoung Chul Cho, Yan Wang, et al.. (2023). LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial. Annals of Oncology. 34. S1307–S1307. 8 indexed citations

Girard, N., K. Park, Kun Tang, et al.. (2023). LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study. Annals of Oncology. 34. S1304–S1304. 5 indexed citations

Haddish‐Berhane, Nahor, Alberto Russu, Meena Thayu, et al.. (2023). Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non‐Small Cell Lung Cancer. Clinical Pharmacology & Therapeutics. 115(3). 468–477. 5 indexed citations

Trigo, José, Byoung Chul Cho, N. Girard, et al.. (2022). 20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC). Annals of Oncology. 33. S38–S39. 2 indexed citations

Girard, N., Joris Diels, Nora Rahhali, et al.. (2022). 19P Stable disease (SD) on amivantamab in post-platinum epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutated non-small cell lung cancer (NSCLC): A response-based analysis. Annals of Oncology. 33. S38–S38. 1 indexed citations

Park, Keunchil, Joshua K. Sabari, Eric B. Haura, et al.. (2022). MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study. Annals of Oncology. 33. S482–S482. 1 indexed citations

Jones, Robin L., Thomas J. Herzog, Shreyaskumar Patel, et al.. (2021). Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Medicine. 10(11). 3565–3574. 10 indexed citations

Drake, Charles G., Russell K. Pachynski, Sumit K. Subudhi, et al.. (2021). Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 25(2). 219–228. 28 indexed citations

Krebs, Matthew, Melissa L. Johnson, Byoung Chul Cho, et al.. (2021). Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.. Journal of Clinical Oncology. 39(15_suppl). TPS3150–TPS3150. 3 indexed citations

10.

Cho, Byoung Chul, Dongwook Kim, Jin Sun Lee, et al.. (2020). 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. Annals of Oncology. 31. S813–S813. 32 indexed citations

11.

Monk, Bradley J., Thomas J. Herzog, George Wang, et al.. (2020). Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer. SHILAP Revista de lepidopterología. 30. 105465–105465. 3 indexed citations

12.

Pillai, Rathi N., Suresh S. Ramalingam, Meena Thayu, et al.. (2020). Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414). JTO Clinical and Research Reports. 2(2). 100104–100104. 11 indexed citations

13.

Park, K., Myung‐Ju Ahn, Min Hee Hong, et al.. (2018). OA10.06 A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 13(10). S344–S345. 7 indexed citations

14.

Schuetze, Scott M., Robert G. Maki, Robin L. Jones, et al.. (2017). Efficacy and safety of patients treated long-term with trabectedin (t) on the expanded access program: A retrospective analysis. Annals of Oncology. 28. v529–v529. 3 indexed citations

15.

Demetri, George D., Margaret von Mehren, Robin L. Jones, et al.. (2015). Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of Clinical Oncology. 34(8). 786–793. 576 indexed citations breakdown →

16.

Monk, B.J., Prafull Ghatage, Trilok Parekh, et al.. (2015). Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Annals of Oncology. 26(5). 914–920. 53 indexed citations

17.

Mehren, Margaret von, Michael A. Bookman, Neal J. Meropol, et al.. (2015). Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 75(5). 1047–1055. 5 indexed citations

18.

Tabernero, Josep, Luc Dirix, Patrick Schöffski, et al.. (2011). A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(19). 6313–6321. 46 indexed citations

19.

Su, Laura F., Roland E. Knoblauch, & Michael J. Garabedian. (2001). Rho GTPases as Modulators of the Estrogen Receptor Transcriptional Response. Journal of Biological Chemistry. 276(5). 3231–3237. 80 indexed citations

20.

Knoblauch, Roland E. & Michael J. Garabedian. (1999). Role for Hsp90-Associated Cochaperone p23 in Estrogen Receptor Signal Transduction. Molecular and Cellular Biology. 19(5). 3748–3759. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact